The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 27, 2022

Filed:

Mar. 05, 2018
Applicant:

Roche Diagnostics Operations, Inc., Indianapolis, IN (US);

Inventors:

Dirk Block, Bichl, DE;

Roberto Latini, Milan, IT;

Serge Masson, Monza, IT;

Ursula-Henrike Wienhues-Thelen, Krailling, DE;

Christian Zaugg, Rheinfelden, CH;

Assignee:

Roche Diagnostics Operations, Inc., Indianapolis, IN (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/68 (2006.01); A61B 5/055 (2006.01); A61B 8/08 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6887 (2013.01); A61B 5/055 (2013.01); A61B 8/0883 (2013.01); G01N 2333/4703 (2013.01); G01N 2333/4706 (2013.01); G01N 2333/4712 (2013.01); G01N 2333/50 (2013.01); G01N 2333/78 (2013.01); G01N 2800/32 (2013.01); G01N 2800/329 (2013.01); G01N 2800/50 (2013.01);
Abstract

The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.


Find Patent Forward Citations

Loading…